O
UTHR icon

OrbiMed’s United Therapeutics UTHR Stock Holding History

OrbiMed’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-105,200
Closed -$51.3M – 131
2025
Q4 		$51.3M Sell
105,200
-9,700
-8% -$4.52M 1.05% 28
2025
Q3 		$48.2M Buy
+114,900
New +$38.6M 1.13% 30
2024
Q1 		– Sell
-386,100
Closed -$84.9M – 126
2023
Q4 		$84.9M Sell
386,100
-15,800
-4% -$3.64M 1.7% 17
2023
Q3 		$90.8M Hold
401,900
– – 1.93% 13
2023
Q2 		$88.7M Buy
+401,900
New +$89M 1.61% 17
2014
Q1 		– Sell
-55,000
Closed -$6.22M – 148
2013
Q4 		$6.22M Buy
+55,000
New +$4.96M 0.09% 91

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

OrbiMed's UTHR Position: Q1 2026 in Review

OrbiMed sold out of United Therapeutics (UTHR) in Q1 2026, closing a stake of 105,200 shares — an estimated $51.3M sold.

OrbiMed first reported a position in UTHR in Q4 2013 and held it in 6 quarters. The position peaked at $90.8M in Q3 2023. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • OrbiMed reported no remaining United Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 105,200 United Therapeutics shares in Q1 2026, an estimated $51.3M.
  • OrbiMed first reported a position in United Therapeutics in Q4 2013 and held it in 6 quarters.
  • OrbiMed's United Therapeutics position peaked at $90.8M in Q3 2023.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.